Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Kosmou, Anastasia [VerfasserIn]   i
 Sachpekidis, Christos [VerfasserIn]   i
 Pan, Leyun [VerfasserIn]   i
 Matsopoulos, George K. [VerfasserIn]   i
 Hassel, Jessica C. [VerfasserIn]   i
 Dimitrakopoulou-Strauss, Antonia [VerfasserIn]   i
 Provata, Astero [VerfasserIn]   i
Titel:Fractal and multifractal analysis of PET-CT images for therapy assessment of metastatic melanoma patients under PD-1 inhibitors
Titelzusatz:a feasibility study
Verf.angabe:Anastasia Kosmou, Christos Sachpekidis, Leyun Pan, George K. Matsopoulos, Jessica C. Hassel, Antonia Dimitrakopoulou-Strauss and Astero Provata
E-Jahr:2021
Jahr:15 October 2021
Umfang:21 S.
Fussnoten:Gesehen am 07.12.2021
Titel Quelle:Enthalten in: Cancers
Ort Quelle:Basel : MDPI, 2009
Jahr Quelle:2021
Band/Heft Quelle:13(2021), 20, Artikel-ID 5170, Seite 1-21
ISSN Quelle:2072-6694
Abstract:Longitudinal whole-body PET-CT scans with F-18-fluorodeoxyglucose (18F-FDG) in patients suffering from metastatic melanoma were analyzed and the tracer distribution in patients was compared with that of healthy controls. Nineteen patients with metastatic melanoma were scanned before, after two and after four cycles of treatment with PD-1 inhibitors (pembrolizumab, nivolumab) applied as monotherapy or as combination treatment with ipilimumab. For comparison eight healthy controls were analyzed. As quantitative measures for the comparison between controls and patients, the nonlinear fractal dimension (FD) and multifractal spectrum (MFS) were calculated from the digitized PET-CT scans. The FD and MFS measures, which capture the dispersion of the tracer in the body, decreased with disease progression, since the tracer particles tended to accumulate around metastatic sites in patients, while the measures increased when the patients’ clinical condition ameliorate. The MFS measure gave better predictions and were consistent with the PET Response Evaluation Criteria for Immunotherapy (PERCIMT) in 81% of the cases, while FD agreed in 77% of all cases. These results agree, qualitatively, with a previous study of our group when treatment with ipilimumab monotherapy was considered.
DOI:doi:10.3390/cancers13205170
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext ; Verlag: https://doi.org/10.3390/cancers13205170
 Volltext: https://www.mdpi.com/2072-6694/13/20/5170
 DOI: https://doi.org/10.3390/cancers13205170
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:fractal dimensions
 ipilimumab
 metastatic melanoma
 multifractal spectrum
 nivolumab
 pembrolizumab
 PET-CT imaging
K10plus-PPN:1780524811
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68809553   QR-Code
zum Seitenanfang